Skip to main content
logo
Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
5.98
+0.45 (8.14%)
At close: Aug 4, 2026, 4:00 PM EDT
6.00
+0.02 (0.33%)
Pre-market: Aug 5, 2026, 5:18 AM EDT

Aclaris Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
8.377.8318.7231.2529.756.76
Revenue Growth
-52.94%-58.19%-40.09%5.03%340.05%4.30%
Gross Profit
6.395.7415.9327.8325.732.05
Operating Income
-80.48-76.38-141.93-97.36-89.85-89.72
Net Income
-69.66-64.92-132.07-88.48-86.91-90.87
Earnings Per Share
-0.56-0.53-1.71-1.27-1.33-1.60
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
105.4290.75113.59119.11217.57191.41
Total Debt
00000.680.69
Net Cash (Debt)
105.4290.75113.59119.11216.89190.72
Net Cash Growth
0.10%-20.11%-4.63%-45.08%13.72%344.83%
Net Cash Per Share
0.850.741.471.713.333.36

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-52.21-47.11-20.08-78.33-67.57-52.13
Capital Expenditures
-0.08-0.11-0.12-1.31-0.61-0.31
Free Cash Flow
-52.29-47.22-20.2-79.63-68.17-52.44
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
76.34%73.28%85.09%89.05%86.48%30.29%
Operating Margin
-961.91%-975.91%-758.18%-311.55%-302.01%-1327.07%
Pretax Margin
-832.58%-829.58%-705.48%-284.32%-292.11%-1343.96%
Profit Margin
-832.58%-829.58%-705.48%-283.15%-292.11%-1343.96%
FCF Margin
-624.91%-603.42%-107.89%-254.84%-229.13%-775.65%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
99.8246.3514.292.3835.30131.68